RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Entry into a Material Definitive Agreement

RADIUS HEALTH, INC. (NASDAQ:RDUS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

Story continues below

Entry into a Material Definitive Agreement.

On July 13, 2017, Radius Health,Inc. (“Radius”) entered into a License and Development Agreement (the “Agreement”) with Teijin Limited (“Teijin”) for abaloparatide for subcutaneous injection (“abaloparatide-SC”) in Japan. Teijin is developing abaloparatide-SC in Japan under an agreement with Ipsen Pharma S.A.S. and has initiated a phase 3 trial in Japanese patients with osteoporosis. Radius and Teijin Pharma Limited (a subsidiary of Teijin) previously entered into a Safety Agreement, dated November 30, 2007, which provides for the exchange of safety information related to abaloparatide-SC to enable safety reporting to global health agencies.

to the Agreement, Radius granted Teijin (i) an exclusive license under certain of Radius’ intellectual property to develop and commercialize abaloparatide-SC in Japan, (ii) a non-exclusive license under certain of Radius’ intellectual property to manufacture abaloparatide-SC for commercial supply in Japan, and (iii) a right of reference to certain of Radius’ regulatory data related to abaloparatide-SC for purposes of developing, manufacturing and commercializing abaloparatide-SC in Japan. In consideration for these rights, Teijin is obligated to pay Radius an upfront payment, to make payments to Radius upon the achievement of certain regulatory and sales milestones, and to pay Radius a royalty based on net sales of abaloparatide-SC in Japan during the royalty term. In addition, Radius has an option to negotiate a co-promotion agreement with Teijin for abaloparatide-SC in Japan.

Teijin granted Radius (i) an exclusive license under certain of Teijin’s intellectual property to develop, manufacture and commercialize abaloparatide-SC outside Japan and (ii) a right of reference to certain of Teijin’s regulatory data related to abaloparatide-SC for purposes of developing, manufacturing and commercializing abaloparatide-SC outside Japan. Radius maintains full global rights to its development program for abaloparatide-transdermal, which is not part of the Agreement. to the Agreement, the parties may further collaborate on new indications for abaloparatide-SC.

Unless earlier terminated, the Agreement expires on the later of the (i) date on which the use, sale or importation of abaloparatide-SC is no longer covered by a valid claim under the Radius patent rights licensed to Teijin in Japan, (ii) expiration of marketing or data exclusivity for abaloparatide-SC in Japan, or (iii) 10th anniversary of the first commercial sale of abaloparatide-SC in Japan. Either party may terminate the Agreement for an uncured material breach or default or a bankruptcy event of the other party. Teijin may terminate the Agreement, with prior notice to Radius, if Teijin reasonably believes that abaloparatide-SC cannot reasonably be developed or commercialized or it cannot continue to commercialize abaloparatide-SC due to reasons of safety, efficacy, pharmaeconomics, economic hardship and/or marketability, and Teijin permanently abandons the development and commercialization of abaloparatide-SC.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement, a copy of which Radius intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2017. A copy of the press release announcing the Agreement is attached hereto as Exhibit 99.1 and is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly provided by specific reference in such a filing.

Item 1.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated July 13, 2017.


Radius Health, Inc. Exhibit
EX-99.1 2 rdus-ex991_6.htm EX-99.1 rdus-ex991_6.htm Exhibit 99.1   Radius Health Announces License and Development Agreement for Abaloparatide-SC with Teijin Limited in Japan   • Teijin granted a right of reference to Radius regulatory data and use of Radius Intellectual Property for development,…
To view the full exhibit click here

About RADIUS HEALTH, INC. (NASDAQ:RDUS)

Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.

An ad to help with our costs